dict.md logo
Choose languages of interest
SELECT >>
English
Advertisement:
Translation
 
0 translations
 
Definition
 
enEnglish
anaplastic thyroid cancer definition: (an-a-PLAS-tik) A rare, aggressive type of thyroid cancer in which the malignant (cancer) cells look very different from normal thyroid cells.
Thyroid Gland Undifferentiated (Anaplastic) Carcinoma definition: A primary carcinoma of the thyroid gland composed of undifferentiated cells. The malignant cells demonstrate evidence of epithelial differentiation, either by immunohistochemistry or electron microscopic studies. Microscopically, in the majority of cases there is a mixture of spindle, epithelioid, and giant cells. The vast majority of the patients present with a rapidly enlarging neck mass. The clinical course is usually aggressive.
 
Examples
 

ARO cells, derived from a thyroid anaplastic carcinoma, were exposed to different concentrations of the drug.

Marilena Celano et al.

BMC Cancer 4 (7), 13 Sep 2004

In contrast, no appreciable response was observed in four patients with aggressive thyroid anaplastic carcinoma treated with combination of gemcitabine and vinorelbine [ 9 ].

Marilena Celano et al.

BMC Cancer 4 (7), 13 Sep 2004

Despite its promising effectiveness derived from a preclinical study [ 8 ], no appreciable response was observed in a clinical study including four patients with aggressive thyroid anaplastic carcinoma treated with combination of gemcitabine and vinorelbine [ 9 ].

Marilena Celano et al.

BMC Cancer 4 (7), 13 Sep 2004

Ain KB Anaplastic thyroid carcinoma: behavior, biology, and therapeutic approaches Thyroid 1998 8 715 726 9737368 Pasieka JL Anaplastic thyroid cancer Curr Opin Oncol 2003 15 78 83 12490766 10.1097/00001622-200301000-00012 Abratt RP Gemcitabine hydrochloride: combination of activity and tolerability (Summary) Anticancer Drugs 1995 6 63 64 Haller DG Chemotherapy for advanced pancreatic cancer Int J Radiat Oncol Biol Phys 2003 56 16 23 12826247 10.1016/S0360-3016(03)00448-6 Fowler WC Jr Van Le L Gemcitabine as a single-agent treatment for ovarian cancer Gynecol Oncol 2003 90 S21 23 12928002 10.1016/S0090-8258(03)00340-8 Harper P Update on gemcitabine/carboplatin in patients with advanced non-small cell lung cancer Semin Oncol 2003 30 2 12 12917815 10.1016/S0093-7754(03)00279-3 Lawrence TS Radiation sensitizers and targeted therapies Oncology (Huntingt) 2003 17 23 28 14723003 Ringel MD Greenberg M Chen X Hayre N Suzuki K Priebat D Saji M Burman KD Cytotoxic activity of 2',2'-difluorodeoxycytidine (Gemcitabine) in poorly differentiated thyroid carcinoma cells Thyroid 2000 10 865 869 11081253 Delord JP Raymond E Chaouche M Ruffie P Ducreux M Faivre S Boige V Le Chevalier T Rixe O Baudin E Pautier P Rodier JM Chouaki N Escudier B Kayitalire L Armand JP A dose-finding study of gemcitabine and vinorelbine in advanced previously treated malignancies Ann Oncol 2000 11 73 79 10690391 10.1023/A:1008352227275 Fossella FV Lippman SM Shin DM Tarassoff P Calayag-Jung M Perez-Soler R Lee JS Murphy WK Glisson B Rivera E Hong WK Maximum-tolerated dose defined for single-agent gemcitabine.

Marilena Celano et al.

BMC Cancer 4 (7), 13 Sep 2004

A phase I dose-escalation study in chemotherapy-naïve patients with advanced non-small-cell lung cancer J Clin Oncol 1997 15 310 316 8996158 Fresta M Panico AM Bucolo C Giannavola C Puglisi G Characterization and in-vivo ocular absorption of liposome-encapsulated acyclovir J Pharm Pharmacol 1999 51 565 576 10411216 10.1211/0022357991772664 Fresta M Puglisi G Reduction of maturation phenomenon in cerebral ischemia with CDP-choline-loaded liposomes Pharm Res 1999 16 1843 1849 10644072 10.1023/A:1018999225435 Russo D Arturi F Bulotta S Pellizzari L Filetti S Manzini G Damante G Tell G Ape1/ref-1 expression and cellular localization in human thyroid carcinoma cell lines J Endocrinol Invest 2001 24 RC10 12 11314755 Wong JP Yang H Blasetti KL Schnell G Conley J Schofield LN Liposome delivery of ciprofloxacin against intracellular Francisella tularensis infection J Control Rel 2003 92 265 273 10.1016/S0168-3659(03)00358-4 Filetti S Bidart JM Arturi F Caillou B Russo D Schlumberger M Sodium/iodide symporter: a key transport system in thyroid cancer cell metabolism Eur J Endocrinol 1999 141 443 457 10576759 Spitzweg C Morris JC The sodium iodide symporter: its pathophysiological and therapeutic implications Clin Endocrinol 2002 57 559 574 10.1046/j.1365-2265.2002.01640.x Nagayama Y Yokoi H Takeda K Hasegawa M Nishihara E Namba H Yamashita S Niwa M Adenovirus-mediated tumor suppressor p53 gene therapy for anaplastic thyroid carcinoma in vitro and in vivo J Clin Endocrinol Metab 2000 85 4081 4086 11095436 10.1210/jc.85.11.4081 Takeda T Inaba H Yamazaki M Kyo S Miyamoto T Suzuki S Ehara T Kakizawa T Hara M DeGroot LJ Hashizume K Tumor-specific gene therapy for undifferentiated thyroid carcinoma utilizing the telomerase reverse transcriptase promoter J Clin Endocrinol Metab 2003 88 3531 3538 12915632 10.1210/jc.2002-021856 To H Ohdo S Shin M Uchimaru H Yukawa E Higuchi S Fujimura A Kobayashi E Dosing time dependency of doxorubicin-induced cardiotoxicity and bone marrow toxicity in rats J Pharm Pharmacol 2003 55 803 810 12841941 10.1211/002235703765951410 Allen TM Liposomes.

Marilena Celano et al.

BMC Cancer 4 (7), 13 Sep 2004

 
Publications
 
0 publications